Novo Nordisk cuts the first turf for new factory  

Today the Danish healthcare company will cut the first turf for a new DKK 800 million factory in Kalundborg for the production of a new diabetes drug

Today healthcare company Novo Nordisk will cut the first turf for a new factory in Kalundborg (west of Copenhagen) for the production of liraglutide, a new Novo Nordisk drug currently under development for the treatment of type 2 diabetes. Studies have shown that liraglutide lowers blood glucose with little or no risk of inducing hypoglycaemia. Liraglutide may also be able to regenerate insulin producing cells (beta cells). The product has completed clinical phase II trials and phase III trials are expected to be initiated in H2 2004.


The new DKK 800 million (USD 128 million) plant in Kalundborg is scheduled for completion in 2005 and will create about 100 new jobs. It is only a year ago since Novo Nordisk inaugurated the world's largest insulin factory in Kalundborg and also started building an insulin purification plant there. Once the new plant for liraglutide production is in operation, Novo Nordisk will employ over two thousand people in the Kalundborg area. The news is reported by financial newspaper Børsen and on Novo Nordisk's website.


Link > Novo Nordisk 

Next step

Explore business cases

Please contact me

How can we help you?

We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×